Nanobiotix vs Xilio Therapeutics
NBTX and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NBTX and XLO compare
Xilio Therapeutics keeps more of each dollar of sales as profit, with a net margin of −20.9% compared with −73.5% at Nanobiotix.
Xilio Therapeutics scores higher on the StockData Score (11 against 3 for Nanobiotix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NBTX | XLO |
|---|---|---|
| Size and price | ||
| Market cap | – | $46.7M |
| Share price | $30.66 | $8.07 |
| Change, 1 year | 42.1% | −25.4% |
| Change, 5 years | 231% | −97.5% |
| Beta (5Y) | 0.47 | 0.89 |
| Employees | 97 | 76 |
| StockData Score | ||
| Total score | 3 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.8× |
| P/B | – | 0.7× |
| FCF yield | – | −123% |
| Fair value | – | $31.67 |
| Margin of safety | – | 74.5% |
| Growth | ||
| Revenue growth (TTM) | – | 73.0% |
| Revenue growth, 5Y average | 67.0% | – |
| Profitability | ||
| Operating margin | −33.2% (better) | −74.9% |
| Net margin | −73.5% | −20.9% (better) |
| FCF margin | −104% (better) | −105% |
| Return on equity | – | −38.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −0.7× | – |
| Current ratio | 1.44 | 4.72 (better) |
| Altman Z-score | – | −3.87 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 12.0% | 58.9% |
| Held by insiders | 0.00% | – |
| Insider net buying, 12 months | – | $38.3K |
Go deeper
- NBTX stock overview
- NBTX income statement
- NBTX valuation and score
- XLO stock overview
- XLO income statement
- XLO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.